Roswell Park to Assess Immunotherapy Combination in Cancer Patients With COVID-19
May 13, 2020
May 13, 2020
BUFFALO, New York, May 13 -- The Roswell Park Comprehensive Cancer Center issued the following news release:
A unique two-drug immunotherapy combination first evaluated at Roswell Park Comprehensive Cancer Center as an approach for treating some cancers will soon be available to cancer patients with COVID-19 through a clinical trial at Roswell Park. The U.S. Food and Drug Administration has authorized clinical researchers at the center to conduct a study assessing the safety and eff . . .
A unique two-drug immunotherapy combination first evaluated at Roswell Park Comprehensive Cancer Center as an approach for treating some cancers will soon be available to cancer patients with COVID-19 through a clinical trial at Roswell Park. The U.S. Food and Drug Administration has authorized clinical researchers at the center to conduct a study assessing the safety and eff . . .